S&N Shareholders Could Hold Out for a Better Deal

Following the latest rumours, we think Smith & Nephew shareholders may be wise to hold out for a higher offer from either J&J or another suitor

Julie Stralow, CFA 13 January, 2011 | 5:47PM
Facebook Twitter LinkedIn

Reports surfaced over the weekend that Johnson & Johnson (JNJ) had submitted a bid for Smith & Nephew (SN.) of £7 billion, or 750 pence per share, that was rejected by the target late last year. Although not confirmed by J&J, as we believe Smith & Nephew is worth about 765 pence per share we think that rumoured bid would have been merely fair, and Smith & Nephew shareholders may be wise to hold out for a higher offer from either J&J or another suitor. From the perspective of J&J's credit rating and fair value estimate, we don't expect the potential deal would cause major changes if it were completed at £7 billion.

Strategically, we think Smith & Nephew's business could be a good fit with J&J, which already operates large orthopaedic, sports medicine, and wound-management businesses. However, we worry that it may be deemed too good a fit by antitrust regulators. For example, in orthopaedics, a combined J&J-Smith & Nephew would become the leading provider of knees and hips in the world, controlling about one third of the market. While not necessarily deal breakers, we think combined market share statistics like those may face intense scrutiny by antitrust regulators around the globe, especially given the difficult entry dynamics associated with the orthopaedics industry. A more palatable deal to regulators, in our opinion, would be the combination of Biomet (private) and Smith & Nephew, which would bring two smaller orthopaedic device makers together, creating a more level playing field between them and the orthopaedic leaders--Zimmer (ZMH), Johnson & Johnson, and Stryker (SYK). Overall though, with reports of rumoured deal terms entering the market, we wouldn't be surprised to see Biomet or other private investors enter the fray, which could help boost future bids for Smith & Nephew as well.

Damien Conover, CFA, contributed to this note.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Smith & Nephew PLC1,157.00 GBX0.87Rating

About Author

Julie Stralow, CFA  Julie Stralow, CFA, is a senior securities analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures